Paper Details

  1. Home
  2. Paper Details

Analysis of the Efficacy and Safety of Avatrombopag Combined With MSCs for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation.

Author: ChenTing, FengYimei, GaoLei, GaoLi, GaoShichun, KongPeiyan, LiuHuanfeng, LiuJia, WangLu, ZhangCheng, ZhangXi, ZhuLidan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the efficacy and safety of avatrombopag combined with mesenchymal stem cells (MSCs) in 16 patients with thrombocytopenia after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The results showed that the combination significantly promoted platelet recovery in 81.3% of patients, with a median time to complete response of 32 days.
Paper Details　
Original Abstract of the Article :
Platelet graft failure (PGF) is a frequent and serious complication after Allogeneic hematopoietic stem cell transplantation (allo-HSCT) and lacks effective treatment strategies, which could affect the prognosis of patients and even cause death. The exact underlying mechanism of PGF remains unclear,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184517/

データ提供：米国国立医学図書館（NLM）

Avatrombopag and MSCs: A New Dawn for Thrombocytopenia?

The struggle with [thrombocytopenia] after [allogeneic hematopoietic stem cell transplantation (allo-HSCT)] can be a challenging hurdle. This research explores a novel combination therapy involving [avatrombopag] and [mesenchymal stem cells (MSCs)] to address this complication. The authors conducted a [retrospective study] of 16 patients with thrombocytopenia after allo-HSCT, analyzing the efficacy and safety of this combined treatment. Their findings suggest that this approach could significantly improve platelet recovery and overall survival in patients with thrombocytopenia following allo-HSCT.

A New Oasis in the Desert of Thrombocytopenia

The study revealed that the combined therapy of avatrombopag and MSCs resulted in [complete response] in 81.3% of patients. This encouraging result suggests that this approach could offer a new and effective treatment option for thrombocytopenia after allo-HSCT.

Navigating the Sands of Treatment

As Dr. Camel, I am cautiously optimistic about the potential of this combined therapy. While the study's findings are promising, further research is needed to confirm its effectiveness and safety in a larger patient population.

Dr.Camel's Conclusion

This research investigates the efficacy and safety of avatrombopag combined with mesenchymal stem cells (MSCs) for the treatment of thrombocytopenia after allogeneic hematopoietic stem cell transplantation. The study suggests that this approach could offer a promising new treatment option, improving platelet recovery and potentially enhancing survival rates. As Dr. Camel, I believe that this research represents a significant step towards a new oasis in the desert of thrombocytopenia, offering hope for a brighter future for patients undergoing allo-HSCT.

Date :
  1. Date Completed 2023-01-04
  2. Date Revised 2023-01-04
Further Info :

Pubmed ID

35693772

DOI: Digital Object Identifier

PMC9184517

Related Literature

Article Analysis
・Effects of avatrombopag
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.